News FDA decision on oral Wegovy coming in Q4 Novo Nordisk has had its NDA for an oral formulation of Wegovy accepted by the FDA. It would be the first obesity-targeted GLP-1 in pill form.
News Lilly hit as PBM drops Zepbound, but retains Wegovy Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.
News Novo Nordisk unleashes Wegovy telehealth blitz Novo Nordisk has enlisted the aid of major telehealth companies as it tries to dominate the self-pay market for obesity drugs in the US.
News Trump blocks plan for Medicare to cover weight-loss drugs A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.
Market Access UK weight loss market: M&A opportunities Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities
News Novo Nordisk's CagriSema data disappoints investors again Novo Nordisk's obesity candidate CagriSema has underwhelmed in a second phase 3 trial, sending the company's share into a sharp decline.
News EMA seeks input on virtual alternative to animal test EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
